GlassScriptPhysician profile
Catherine Millet
NPI 1740678317
$10,361.41
in general payments reported to CMS, 2019-2025
29 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,490 · 2022: $2,327 · 2023: $2,134 · 2024: $1,824 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,536 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,535.80 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,095.53 | 2021-2025 | |
| Genzyme Corporation | $1,496.76 | 2021-2025 | |
| Leo Pharma INC. | $770.28 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $662.73 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Allergan, INC. | $609.29 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $509.83 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $478.10 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $416.25 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $330.11 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $303.41 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $293.03 | 2021-2025 | |
| Amgen INC. | $278.87 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $277.46 | 2021-2023 | Cimzia |
| Incyte Corporation | $258.86 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $217.89 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $217.48 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $191.95 | 2021-2024 | Jublia, Arazlo, Duobrii |
| E.R. Squibb & Sons, L.L.C. | $171.15 | 2021-2024 | Sotyktu |
| Organon LLC | $137.96 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $129.58 | 2021 | |
| Janssen Scientific Affairs, LLC | $121.87 | 2022 | |
| Pfizer INC. | $115.28 | 2022-2025 | |
| Journey Medical Corporation | $98.31 | 2022 | |
| Biofrontera INC. | $61.52 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Merz North America, INC. | $36.61 | 2021-2024 | |
| Integra Lifesciences Corporation | $28.73 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Dermira, INC. | $21.25 | 2021 | |
| Botanix Sb INC | $19.44 | 2025 | Sofdra |
| Medtronic, INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Millet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.